New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
17:13 EDTABT, NEOAbbott reports 7.73% passive stake in NeoGenomics
News For ABT;NEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
11:02 EDTABTAbbott to purchase Tendyne Holdings, Cephea Valve Technologies
Subscribe for More Information
July 23, 2015
07:51 EDTNEONeoGenomics lowers FY15 revenue guidance to 100M-$103M from $103M-$108M
Consensus $103.78M. NeoGenomics reiterated its expectation of a return to profitability in the second half of 2015.
07:21 EDTNEONeoGenomics reports Q2 EPS 0c, consensus (1c)
Subscribe for More Information
July 22, 2015
10:06 EDTABTAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:33 EDTABTAbbott sees Q3 Diagnostics sales up mid single digits on operational basis
Subscribe for More Information
09:30 EDTABTAbbott CEO says 'pretty alligned' with Mylan so far
09:15 EDTABTAbbott sees FY15 reported sales growth to be in low single digits
Subscribe for More Information
09:15 EDTABTAbbott sees Q3 EPS 52c-54c, consensus 55c
Sees Q3 impact from foreign exchange to be "somewhat above" 9% based on current exchange rates, resulting in reported sales growth in the low single digits, consensus $5.19B. Guidance from Q2 earnings call.
09:07 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTABTAbbott says foreign exchange impacting results more than expected in January
Subscribe for More Information
07:49 EDTABTAbbott reports Q2 Nutrition sales $1.72B, Diagnostics sales $1.18B
Subscribe for More Information
07:48 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.16
Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately 60c per share.
07:47 EDTABTAbbott reports Q2 adjusted EPS 52c, consensus 50c
Subscribe for More Information
07:09 EDTNEONeoGenomics expands multimodality cancer profile testing
NeoGenomics expanded its comprehensive multimodality NeoTYPE tumor-type specific cancer profiling tests to include new profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and for cancers of unknown primary. These new tests integrate a variety of technologies, including next generation sequencing, viral in-situ hybridization, FISH, and immunohistochemistry. A number of new tests are being added to NeoGenomics cancer diagnostic test menu.
July 21, 2015
15:02 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use